AIMEDBIO
IR
ENG
KOR
ABOUT US
Overview
Leadership
Corporate Governance
R&D
AimedBio’s Drug Development
P-ADC™
Pipeline
IR
Disclosure
Stock
Financial Information
PR
Notice
Press Release
Data Room
CAREERS
Our Culture
Disclosure
48 posts
NO.
Title
Date
Author
48
Material Management Information related to Judgment of Investment (ODS025 기술이전계약 관련 연구개발비 수령)
2026-05-06
에임드바이오
47
Report on the Grant of Stock Options
2026-03-27
에임드바이오
46
Outcomes of Annual Meeting of Shareholders
2026-03-27
에임드바이오
45
Forecast on Business Performance according to Consolidated Financial Statements(Fair Disclosure)
2026-03-26
에임드바이오
44
Annual Report (2025.12)
2026-03-19
에임드바이오
43
Submission of Audit Report
2026-03-19
에임드바이오
42
Report on status of specific securities, etc. owned by executives and major shareholders
2026-03-17
인터베스트
41
Report on significant holdings of stocks, etc. (Short form)
2026-03-17
인터베스트
40
Reference documents for proxy solicitation
2026-03-12
에임드바이오
39
Announcement of convocation of general meeting of shareholders
2026-03-12
에임드바이오
Material Management Information related to Judgment of Investment (ODS025 기술이전계약 관련 연구개발비 수령)
에임드바이오
2026-05-06
Report on the Grant of Stock Options
에임드바이오
2026-03-27
Outcomes of Annual Meeting of Shareholders
에임드바이오
2026-03-27
Forecast on Business Performance according to Consolidated Financial Statements(Fair Disclosure)
에임드바이오
2026-03-26
Annual Report (2025.12)
에임드바이오
2026-03-19
Submission of Audit Report
에임드바이오
2026-03-19
Report on status of specific securities, etc. owned by executives and major shareholders
인터베스트
2026-03-17
Report on significant holdings of stocks, etc. (Short form)
인터베스트
2026-03-17
Reference documents for proxy solicitation
에임드바이오
2026-03-12
Announcement of convocation of general meeting of shareholders
에임드바이오
2026-03-12
1
2
3
4
5
